File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Drug-related problems in hospitalised children in the United Kingdom and Saudi Arabia

TitleDrug-related problems in hospitalised children in the United Kingdom and Saudi Arabia
Authors
KeywordsPharmacy and pharmacology
Issue Date2011
PublisherAdis International Ltd. The Journal's web site is located at http://drugsafety.adisonline.com/
Citation
The 11th Annual Meeting of the International Society of Pharmacovgilance (ISOP 2011), Istanbul, Turkey, 26-28 October 2011. In Drug Safety, 2011, v. 34 n. 10, p. 983, abstract no. PP166 How to Cite?
AbstractBACKGROUND: Drug-related problem (DRP) is ‘‘an event or circumstance involving drug therapy that actually or potentially interferes with the desired health outcome’’.[1] The extent and characteristics of DRPs in children in the UK and Saudi Arabia (KSA) is unknown. AIM: Our aim was to identify the incidence and characteristics of DRPs in children attending A&E/admitted to a hospital in the two countries. METHODS: A prospective cohort study in children aged 0–18 years admitted to the medical ward, paediatric intensive care unit (PICU), and neonatal intensive care unit (NICU) or attending A&E during a three month period in two hospitals were carried out. Data were collected on a form adapted from the Pharmaceutical Care Network in Europe (PCNE) DRP-Registration Form V5.01. Patients’ charts, medical records and laboratory data were reviewed daily to identify DRPs; their preventability and severity were assessed. RESULTS: 990 children [median 3 years, IQR; 10 months – 8 years, 58.6% male] were included. 388 patients suffered from 546 DRPs. Overall DRP incidence was 39.2% (95% CI, 36.1, 42.3) being higher in KSA than in the UK (44.8% vs 33.3%, p< 0.001). Incidence was found to be highest in PICU (59.7%; 95% CI, 47.0, 71.5). Dosing problems were the most frequently reported DRPs (n= 303, 55.5%), followed by drug choice problems (n = 91, 16.7%). 80.0% of DRP cases were preventable; 71.4% (n = 390) DRPs were assessed as minor and 27.8%(n = 152) as moderate. 295 (54.0%) were totally resolved, of which 220 (74.6%) were resolved by pharmacists. CONCLUSIONS: DRPs are a significant problem in the paediatric population in the UK and KSA, the majority of which are preventable. Increased focus on paediatric pharmacology and pharmacotherapy within paediatric medical and nursing education is an important step in improving prescribing practices.
DescriptionPoster Presentations: PP166
This journal issue contain abstracts of the 11th ISoP Annual Meeting
Persistent Identifierhttp://hdl.handle.net/10722/165608
ISSN
2015 Impact Factor: 3.206
2015 SCImago Journal Rankings: 1.359

 

DC FieldValueLanguage
dc.contributor.authorRashed, ANen_US
dc.contributor.authorNeubert, Aen_US
dc.contributor.authorTomlin, Sen_US
dc.contributor.authorJackman, Jen_US
dc.contributor.authorAlhamdan, Hen_US
dc.contributor.authorShaikh, Aen_US
dc.contributor.authorAttar, Aen_US
dc.contributor.authorAseeri, Men_US
dc.contributor.authorWong, ICKen_US
dc.date.accessioned2012-09-20T08:21:12Z-
dc.date.available2012-09-20T08:21:12Z-
dc.date.issued2011en_US
dc.identifier.citationThe 11th Annual Meeting of the International Society of Pharmacovgilance (ISOP 2011), Istanbul, Turkey, 26-28 October 2011. In Drug Safety, 2011, v. 34 n. 10, p. 983, abstract no. PP166en_US
dc.identifier.issn0114-5916-
dc.identifier.urihttp://hdl.handle.net/10722/165608-
dc.descriptionPoster Presentations: PP166-
dc.descriptionThis journal issue contain abstracts of the 11th ISoP Annual Meeting-
dc.description.abstractBACKGROUND: Drug-related problem (DRP) is ‘‘an event or circumstance involving drug therapy that actually or potentially interferes with the desired health outcome’’.[1] The extent and characteristics of DRPs in children in the UK and Saudi Arabia (KSA) is unknown. AIM: Our aim was to identify the incidence and characteristics of DRPs in children attending A&E/admitted to a hospital in the two countries. METHODS: A prospective cohort study in children aged 0–18 years admitted to the medical ward, paediatric intensive care unit (PICU), and neonatal intensive care unit (NICU) or attending A&E during a three month period in two hospitals were carried out. Data were collected on a form adapted from the Pharmaceutical Care Network in Europe (PCNE) DRP-Registration Form V5.01. Patients’ charts, medical records and laboratory data were reviewed daily to identify DRPs; their preventability and severity were assessed. RESULTS: 990 children [median 3 years, IQR; 10 months – 8 years, 58.6% male] were included. 388 patients suffered from 546 DRPs. Overall DRP incidence was 39.2% (95% CI, 36.1, 42.3) being higher in KSA than in the UK (44.8% vs 33.3%, p< 0.001). Incidence was found to be highest in PICU (59.7%; 95% CI, 47.0, 71.5). Dosing problems were the most frequently reported DRPs (n= 303, 55.5%), followed by drug choice problems (n = 91, 16.7%). 80.0% of DRP cases were preventable; 71.4% (n = 390) DRPs were assessed as minor and 27.8%(n = 152) as moderate. 295 (54.0%) were totally resolved, of which 220 (74.6%) were resolved by pharmacists. CONCLUSIONS: DRPs are a significant problem in the paediatric population in the UK and KSA, the majority of which are preventable. Increased focus on paediatric pharmacology and pharmacotherapy within paediatric medical and nursing education is an important step in improving prescribing practices.-
dc.languageengen_US
dc.publisherAdis International Ltd. The Journal's web site is located at http://drugsafety.adisonline.com/-
dc.relation.ispartofDrug Safetyen_US
dc.subjectPharmacy and pharmacology-
dc.titleDrug-related problems in hospitalised children in the United Kingdom and Saudi Arabiaen_US
dc.typeConference_Paperen_US
dc.identifier.emailWong, ICK: wongick@hku.hken_US
dc.identifier.authorityWong, ICK=rp01480en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.2165/11596230-000000000-00000-
dc.identifier.hkuros207303en_US
dc.identifier.volume34en_US
dc.identifier.issue10en_US
dc.identifier.spage983en_US
dc.identifier.epage983en_US
dc.publisher.placeNew Zealand-
dc.description.otherThe 11th Annual Meeting of the International Society of Pharmacovgilance (ISOP 2011), Istanbul, Turkey, 26-28 October 2011. In Drug Safety, 2011, v. 34 n. 10, p. 983, abstract no. PP166-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats